fbpx
Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

Leqembi (lecanemab) authorized for early alzheimer’s disease in Great Britain – Eisai + Biogen

Written by | 31 Aug 2024

Eisai Co., Ltd. and Biogen Inc. announced that the humanized amyloid-beta (Abeta monoclonal antibody “Leqembi” (brand name, generic name: lecanemab) has been granted a Marketing Authorization by the… read more.

FDA approval & authorization for Omicron KP.2-adapted COVID-19 Vaccine – BioNTech SE + Pfizer

Written by | 30 Aug 2024

Pfizer Inc. and BioNTech SE announced that the FDA has approved the supplemental Biologics License Application for individuals 12 years of age and older (COMIRNATY (COVID-19 Vaccine, mRNA),… read more.

Update on cannabidiol oral solution phase III trial in Japan in treatment-resistant epilepsies – Jazz Pharma

Written by | 29 Aug 2024

Jazz Pharmaceuticals plc announced top-line results from the Phase III open-label, single-arm trial in Japan evaluating the safety and efficacy of cannabidiol oral solution (marketed as Epidiolex/Epidyolex globally)… read more.

Abbott advances heart failure management with aspirin free regimen for patients receiving the HeartMate 3 heart pump

Written by | 27 Aug 2024

Abbott announced that the FDA has approved a change to its label that will help patients who receive a HeartMate 3 left ventricular assist device (LVAD, or heart… read more.

FDA approval for IPX 203 for treatment of Parkinson’s disease to be launched as Crexont (carbidopa and levodopa) extended-release capsules – Amneal Pharma

Written by | 26 Aug 2024

Amneal Pharmaceuticals, Inc., announced that the FDA has approved Crexont (carbidopa and levodopa) extended-release capsules for the treatment of Parkinson’s disease (PD). Crexont is a novel, oral formulation… read more.

European Medicines Agency validates application for CAR-T cell therapy Breyanzi, for relapsed or refractory follicular lymphoma – BMS

Written by | 25 Aug 2024

Bristol Myers Squibb announced that the European Medicines Agency (EMA) has validated its Type II variation application to expand the indication for Breyanzi (lisocabtagene maraleucel; liso-cel), a CD19-directed… read more.

Fasenra (benralizumab) approved in China for the treatment of severe eosinophilic asthma – AstraZeneca

Written by | 24 Aug 2024

AstraZeneca’s Fasenra (benralizumab) has been approved in China by the country’s National Medical Products Association (NMPA) for the maintenance treatment of patients 12 years of age and older… read more.

FDA approves for Nemluvio (nemolizumab) for adult patients living with prurigo nodularis – Galderma

Written by | 23 Aug 2024

Galderma announced that the FDA has approved Nemluvio (nemolizumab) as a pre-filled pen for subcutaneous injection for the treatment of adults with prurigo nodularis. Nemluvio was granted Breakthrough… read more.

FDA approval sought for UGN 102 in low-grade, intermediate-risk, non–muscle-invasive, bladder cancer – Urogen Pharma

Written by | 22 Aug 2024

A new drug application (NDA) has been submitted to the FDA seeking the approval of mitomycin for intravesical solution (UGN 102) for the treatment of patients with low-grade,… read more.

Enhertu approved in China for patients with previously treated HER2-positive advanced or metastatic gastric cancer – AstraZeneca + Daiichi Sankyo

Written by | 21 Aug 2024

AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) has received conditional approval in China as a monotherapy for the treatment of adult patients with locally advanced or metastatic HER2-positive… read more.

Bavarian Nordic submits data to EMA to extend Mpox/Smallpox vaccine approval to adolescents

Written by | 20 Aug 2024

Bavarian Nordic A/S has submitted clinical data to the European Medicines Agency (EMA) to support the extension of the Imvanex (MVA-BN ) smallpox and mpox vaccine indication to… read more.

FDA approval of supplemental new drug application expanding the Furoscix (furosemide injection) indication in heart failure – sc Pharmaceuticals

Written by | 19 Aug 2024

scPharmaceuticals Inc. announced that the FDA has approved its Supplemental New Drug Application (sNDA) seeking to expand the Furoscix indication for heart failure patients. At approval, Furoscix was… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.